Two ULK3-targeting drugs were identified, one of which has gained approval for the treatment of chronic myeloid leukemia, while another has demonstrated potential in mitigating cardiac ischemia/reperfusion injury. This evidence concerns the gene ULK3 and myocardial ischemia.